Anheuser-Busch InBev SA/NV (NYSE: BUD) — The Deleveraging Is Almost Done; Now You Own a No-Growth Volume Business at a Growth-Optionality Price

Independent equity research — an independent analyst’s note Report date: 2026-07-11 Security: BUD (NYSE ADR; 1 ADR = 1 ordinary share). Reporting currency: USD. Foreign private issuer (Belgium) — files Form 20-F + 6-K.

⚡ Claude’s Take

This block is the author’s own subjective opinion and general information, not investment advice. The analytical sections that follow take no position and carry no price target; the single view expressed here is the author’s alone.

Verdict: HOLD — a high-quality global franchise whose easiest money (balance-sheet repair) has already been made, now fairly-to-fully valued after a ~70% recovery off the lows. Constructive on the business, neutral on the stock at ~$80. Accumulate-on-weakness in the ~$60–68 zone; trim/avoid chasing above ~$88–92. Conviction: medium.

AB InBev is the best distribution-and-brand machine in global beer — ~26–27% of the world’s beer volume, a portfolio (Corona, Budweiser, Stella, Michelob Ultra, Modelo ex-US, plus regional monopolistic positions in Brazil, Mexico, Colombia, South Africa) that no competitor can replicate, and a genuine, quantifiable moat in route-to-market scale that now includes a $53B-GMV B2B software layer (BEES). But the equity has spent a decade paying for the sin of 2016: management bought SABMiller for ~$100B+ at the top of the cycle, loaded ~$100B of debt and ~$118B of goodwill onto the balance sheet, and has spent nine years grinding it down. That grind is now ~80% complete — net leverage is ~2.87x (company basis), down from ~4.8x, dividends are rising 15% a year, and a $6B buyback is running. The result: underlying EPS has compounded ~6.7%/yr since 2021 on only ~3–4% EBITDA growth, the gap financed by falling interest expense. That is real, but it is a self-liquidating tailwind — once leverage hits ~2x, the deleveraging kicker fades and you are left owning a low-single-digit-volume-growth, mid-single-digit-EBITDA-growth business at ~9.5–10x EV/EBITDA and ~21x underlying earnings.

The framing is “recovering fallen angel, now re-rated.” This is not a falling knife (the tape has flipped decisively positive: rs_6m +28%, +70% off the January-2025 low, price above all major moving averages) and it is not deep value (the valuation sits around the 58th percentile of its own history — mid-range, not cheap). It is a low-beta (0.34), weak-dollar-levered (USD factor beta −0.47), dividend-and-min-vol name that the market has re-embraced as the deleveraging de-risked and the US business (Michelob Ultra, Busch Light) turned. Most of the obvious upside from balance-sheet normalization is now in the price. What would flip me bullish: durable volume growth returning (not just price/mix) — a return to +2–3% organic volumes across Brazil + US + a stabilized China — which would re-rate this toward a true staples multiple. What would flip me bearish: evidence that beer volumes are in structural, GLP-1/moderation-driven secular decline in the developed world and that EM per-capita growth is stalling, which would expose the ~$59B net-debt tower on a shrinking-volume base. Tag: “The turnaround worked — that’s exactly why it’s no longer cheap.”

📈 Stock Price Action — Five-Year Event Map

AB InBev has round-tripped a full cycle and then some. From a COVID crash low near $35 (Mar 2020), the ADR spent 2021–2024 grinding lower on emerging-market currency debasement, the Bud Light boycott, and China weakness — bottoming at $46 in January 2025 — before staging a powerful ~70% recovery to ~$85 (June 2026) on completed deleveraging, margin expansion, and a US turnaround. It trades at $79.61 (2026-07-10), roughly 7% off the June high, with a 52-week range of ~$57–$85. Note the multi-year context: the stock traded near $110–130 in 2016–2017 right after the SABMiller deal closed — a decade later it is ~40% below that level even after the recent rally. The price move is a FACT; the attributed cause is INTERPRETATION.

Cycle narrative. (1) The 2020 crash was a levered-defensive’s worst case — an over-indebted staple hit by a demand shock. (2–4) The 2021–2024 malaise was not an earnings collapse but a slow bleed: EBITDA in USD went sideways as ~70%-EM-weighted revenue was translated through collapsing emerging-market currencies, while the market refused to pay up for a business still carrying >3.5x leverage. (3) The Bud Light episode is instructive — the single most-publicized brand crisis in modern beer barely dented the stock, because the US is a minority of AB InBev’s profit and Modelo/Michelob absorbed the mix. (5–8) The 2025–2026 recovery is a de-risking re-rate: as leverage crossed below ~2.9x, the dividend inflected, the buyback returned, and the US business turned, the market re-rated the equity from “distressed levered staple” back toward “quality global compounder,” compounded by improving volume momentum into 2026 and World Cup/Olympics activation optimism.

1. Executive Summary

Anheuser-Busch InBev is the largest brewer on earth: ~$59.3B of FY2025 revenue, ~26–27% of global beer volume, ~500 brands, operations spanning North America, Middle Americas (Mexico), South America (Brazil/Argentina), EMEA (Europe, South Africa), and APAC (China, South Korea). It owns category-defining global brands (Budweiser, Corona ex-US, Stella Artois, Michelob Ultra) layered on top of near-monopolistic local positions — Ambev in Brazil, Grupo Modelo in Mexico (~56% share), Bavaria in Colombia, and AB in South Africa — that generate the bulk of the profit pool. Roughly 70% of EBITDA comes from emerging and developing markets, which are projected to supply 80%+ of global beer volume growth through 2029.

The business is a genuinely good one wrapped around a balance sheet that has, for a decade, been the whole story. In 2016 AB InBev acquired SABMiller for >$100B, creating ~$118B of goodwill and taking gross debt to ~$100B (net debt/EBITDA ~4.8x). Everything since — two dividend cuts (2018, 2020), suppressed capital returns, a de-rating from ~$110–130 to a $46 low — has been the market discounting that leverage. That chapter is now closing. Net leverage is ~2.87x (company basis) and falling; the dividend rose 15% in 2025; a $6B buyback is running; FCF is a robust ~$11B/yr on ~$3.7B of capex (well below the ~$5.7B of D&A). Underlying EPS has compounded ~6.7%/yr since 2021 — impressive given ~2% revenue and ~4–5% EBITDA growth — with the wedge financed by falling interest expense as the debt shrinks.

The catch is what happens after deleveraging. On the numbers, AB InBev is a ROIC ≈ WACC business: return on invested capital has sat at ~5.8–6.9% every year since 2019, against a cost of capital of ~7–8%. The consolidated returns are depressed by the acquisition goodwill, but even normalizing, this is a low-real-growth, price/mix-driven volume business facing genuine secular questions in the developed world (moderation, Gen Z drinking less, GLP-1 drugs) offset by EM per-capita runway and premiumization. The moat is real and quantifiable — distribution scale, brand equity, and now the BEES digital platform — but it produces stability and pricing power, not compounding returns on incremental capital.

At ~$79.61 the equity trades at ~9.5–10x EV/EBITDA, ~21x underlying EPS, and a ~7% free-cash-flow yield — the 58th percentile of its own valuation history, i.e. mid-range after a large recovery, not distressed. The embedded expectation is mid-single-digit EBITDA growth continuing with leverage normalizing toward ~2x — a reasonable base case that the current price largely reflects. The asymmetry that existed at $46 (a distressed multiple on a de-risking balance sheet) has been harvested. From here, returns depend on the harder question: can AB InBev convert its unmatched footprint into durable volume growth, or is it a bond-like, low-growth, dividend-and-buyback compounder that has already re-rated to fair value? This memo argues the latter is the base case, with the former the bull option — and that the risk/reward at ~$80 is balanced, not compelling.

2. Business Overview

What it does. AB InBev brews, markets, and distributes beer and, increasingly, adjacent beverages (non-alcohol beer, “Beyond Beer” ready-to-drink cocktails and flavored malt/spirits, and — via bottling agreements, notably with PepsiCo in Latin America — soft drinks). It is the product of three decades of serial mega-mergers: Interbrew (Belgium) + AmBev (Brazil) → InBev (2004); InBev + Anheuser-Busch (US) → AB InBev (2008); and AB InBev + SABMiller (2016), which added Africa, Australia, and much of Latin America (parts of the latter, e.g. the Australian Carlton & United business, were subsequently divested to Asahi to clear regulators).

How it makes money. Beer is a classic high-gross-margin, distribution-intensive consumer staple. AB InBev buys agricultural inputs (barley/malt, hops, rice/corn), water, and packaging (aluminum cans, glass, PET), brews at scale, and sells through a mix of company-owned and third-party wholesale distribution into the on-trade (bars, restaurants) and off-trade (retail). Gross margin is ~56%; the spread between that and a ~26% operating margin is sales & marketing (~$7.4B/yr, ~12–13% of revenue — beer is a brand business where advertising is the moat maintenance capex) plus distribution and admin. The economics are driven by revenue per hectoliter (price × mix) far more than by volume: FY2025 revenue grew +2% organically on negative volume, entirely via +4.4% revenue/hl from pricing and premiumization.

Revenue segmentation. AB InBev reports five geographic segments:

• North America (US + Canada) — the highest-margin developed market; home of Bud Light, Budweiser, Michelob Ultra, Busch, Stella, and the fast-growing Beyond Beer portfolio (Cutwater, NÜTRL, Phorm Energy). Structurally challenged on volume; the US turnaround (Michelob Ultra, Busch Light) is a 2025–2026 bright spot.
• Middle Americas (Mexico + Colombia + others) — Grupo Modelo (~56% Mexican share; owns Corona, Modelo, Victoria, Pacífico for export ex-US) and Bavaria (Colombia). High-growth, high-margin, premiumizing.
• South America (Brazil + Argentina + others) — Ambev, a listed subsidiary; the single largest volume pool. Brazil dominates; Argentina adds hyperinflation-accounting noise.
• EMEA (Europe + South Africa + rest of Africa) — mature/premiumizing Europe (Stella, Leffe, Jupiler, Corona) plus a strong, growing South African business (Castle, Carling).
• Asia Pacific (China + South Korea + India + others) — premium-skewed China (Budweiser, Harbin, Sedrin), currently the problem child (revenue down low-teens in 2025 on channel/geographic mix shifts and a weak on-trade).

Recurring vs. non-recurring. Beer demand is highly recurring and non-cyclical in volume terms (people drink through recessions), but reported revenue is buffeted by FX translation (~70% EM-sourced) and by hyperinflationary accounting in Argentina. The recurring core is one of the most predictable cash-flow streams in consumer staples; the noise is almost entirely below the operating line (FX, interest, mark-to-market on hedges) and in translation.

Verdict: A globally-scaled, brand-led, distribution-intensive beverage business with predictable underlying volumes, strong pricing power, and a profit pool concentrated in a handful of near-monopolistic emerging markets. The model is sound; the questions are about growth and the legacy balance sheet, not about business quality.

3. Industry Dynamics

Structure. Global beer is a consolidated oligopoly at the top and fragmented craft/regional tail beneath it. AB InBev produced 495.5m hL in 2024 (~26–27% of global volume) — roughly double #2 Heineken (240.7m hL) and more than 4x #3 China Resources (Snow, 108.8m hL, China-only, the single largest brand by volume). Carlsberg (structurally shrunk after the Russian nationalization of Baltika), Molson Coors, Asahi, Tsingtao, and Kirin fill out the top tier; the world’s 40 largest brewers made 1.64bn hL in 2024, itself down 0.6% YoY. Consolidation has largely run its course — regulators blocked the obvious remaining combinations, and AB InBev is now a forced deconsolidator (it sold assets to fund the SABMiller integration). The profit pool is highly concentrated by geography: a disproportionate share sits in a few markets where one or two players hold >50% share — Mexico (Grupo Modelo ~56–57% share, the world’s 4th-largest beer profit pool), Brazil (Ambev dominant), Colombia, South Africa — precisely the markets AB InBev leads. This is the Greenwald lens at work: beer’s genuine economics live where local scale + captive distribution create regional near-monopolies, not in the fragmented global aggregate.

The central structural irony (critical for a US-listed BUD). AB InBev owns the Corona/Modelo economics almost everywhere on earth — except the single richest developed profit pool, the United States, where the perpetual, exclusive US rights to brew and sell Modelo and Corona belong to Constellation Brands (STZ) as a 2013 antitrust remedy from AB InBev’s own Grupo Modelo acquisition. So the two brands winning US beer (Modelo Especial is the US dollar-share leader) enrich a rival’s P&L, not BUD’s. A US investor buying BUD is buying the global Corona/Modelo franchise minus its best market.

Market size & growth. Global beer is a ~$650–700B retail category by value, growing low-single-digits in value (price/premiumization) on roughly flat-to-slightly-positive global volume. The critical bifurcation:

• Developed markets (US, Western Europe, ~30% of profit): volume in structural, arguably accelerating, slow decline. US off-premise beer volume fell −2.6% in 2024; US production + imports fell −5.7% in 2025. Three simultaneous secular headwinds live here: (i) moderation — the share of Americans who drink fell from 62% (2023) to 54% (2025, Gallup), and Gen Z drinks roughly a third less beer/wine than prior generations; (ii) GLP-1 weight-loss drugs — RCT and survey evidence shows semaglutide users cutting weekly alcohol intake ~41%, with ~45% of GLP-1 users who drink weekly reporting reduced consumption (beer −43% among cutters, somewhat less exposed than wine −52%); and (iii) cannabis/THC-beverage substitution — beer shipments fell −1.9%/yr in recreational-cannabis states vs −0.7%/yr elsewhere, with intoxicating-hemp beverages a fast-growing new competitor. The only offsets are premiumization (above-premium is now >half of US volume) and non-alcohol beer (+20–34%/yr, but small in absolute terms).
• Emerging markets (~70% of EBITDA): low per-capita consumption with a long runway (Africa, parts of LatAm), favorable demographics, and category penetration gains. Management cites IWSR forecasts that beer will keep gaining share of total alcohol (>200bps since 2021) and that EM supplies 80%+ of category volume growth through 2029. Brazil per-capita is already ~70–77 L/yr; the runway is in Africa and under-penetrated Asia.

Competitive intensity. Rational, not ruinous. The global majors compete on brand and distribution rather than price in most markets; the discipline of an oligopoly (few players, high fixed costs, brand-based differentiation) generally holds. Local price wars flare (Brazil vs. Heineken’s Ambev-challenger push; China’s regional battles), and a rising threat is Diageo’s Guinness, growing +13% globally in 2025 (four straight double-digit years). But the structure rewards the scale leader; new entry at the global level is effectively impossible; entry at the craft/local level is easy but caps out at low share and rarely threatens the core.

Regulation & tariffs. Beer is heavily regulated: excise taxes (a large share of shelf price in many markets), the US three-tier distribution system (which, paradoxically, entrenches incumbents by mandating independent wholesalers with whom scale brewers have deep relationships), advertising restrictions, and periodic “sin”-tax and health-labeling pressure. Regulation is a barrier to entry and a moat-reinforcer more than a threat, though tax hikes are a recurring margin risk. A notable 2025 development: effective April 4, 2025 the US imposed a 25% Section 232 tariff on imported canned beer and empty aluminum cans. Beer itself is largely USMCA-exempt, but the packaging is hit — a cost headwind that falls hardest on Constellation (which imports 100% of its beer from Mexico) and is therefore a mild relative advantage for AB InBev’s US-domestically-brewed brands.

Verdict: structurally fair-to-good, not great, and bifurcated. The industry is a rational oligopoly with high entry barriers and pricing power — genuinely attractive attributes. But the developed-market volume base is in secular, likely-accelerating decline against three real demand threats, and the growth is concentrated in EM markets that carry currency, political, and macro risk. Net: a defensible, cash-generative industry with a low structural growth ceiling in the aggregate — you are paid to own the scale leader, not to expect category growth.

4. Competitive Position

The moat, named. AB InBev’s advantage is, in Greenwald’s taxonomy, primarily economies of scale combined with customer captivity in distribution, reinforced by intangible brand assets. Concretely:

1. Route-to-market scale. In its core markets AB InBev operates the densest, most efficient distribution network in beer — reaching millions of fragmented points of sale (bars, small retailers, restaurants) at a cost per drop no sub-scale competitor can match. In a business where the retailer is small and the product is heavy, low-value-per-unit, and perishable-ish, distribution density is the barrier. This is a supply-side scale economy that compounds locally: the leader in a given market has the lowest per-unit logistics cost and the best shelf/tap access.

2. The BEES platform — a widening moat. BEES is AB InBev’s proprietary B2B e-commerce/ordering app for its retail customers, now processing $52.5B of GMV (+12%), live in 29 markets, and capturing ~72% of AB InBev’s total revenue through the B2B digital channel — with a fast-growing third-party Marketplace ($3.5B GMV, +61%, 500+ brands/distributors) that lets non-beer CPGs sell through AB InBev’s digital rail to the same fragmented retailers. This is the most important competitive development at the company in a decade: it deepens customer captivity (the retailer runs its whole order-book — and increasingly payments and credit — through AB InBev’s app), generates proprietary demand data, adds an incremental high-margin revenue stream, and raises switching costs. Management notes beer is only ~34–40% of what these retailers buy — the Marketplace addresses the other ~60%. It is a genuine, quantifiable, network/data/switching-cost widening of the distribution moat, and the single best evidence of a durable, growing advantage in the whole story.

3. Brand equity. A portfolio of brands with real pricing power — Corona sells at a ~20% premium to its nearest competitor and was ranked the most valuable beer brand globally; Michelob Ultra has become the growth engine of US beer; Budweiser, Stella, and the local champions (Brahma, Skol, Aguila, Castle, Jupiler) anchor their markets. Brand is the demand-side captivity that lets AB InBev take price ahead of cost.

4. Procurement & production scale. As the largest buyer of barley, aluminum, and packaging in the industry, AB InBev has a genuine input-cost advantage, and its ZBB (zero-based-budgeting) cost culture — the 3G Capital heritage — is best-in-class at converting scale into margin.

Where the moat is weakest. The moat protects share and margin, not volume growth. It does little against secular category decline (a wide moat around a slowly-draining pool), and it is weak in markets where AB InBev is not the scale leader (China, where it is premium-skewed and sub-scale in the mass segment — APAC organic revenue fell −6.5% in FY2025). The 2023 Bud Light episode is the clearest stress-test of the brand moat and it failed: a single marketing misstep (the April-2023 Dylan Mulvaney partnership and the boycott that followed) saw Bud Light sales fall 11–26% within a month, cost ~$1.4B of US sales, wiped >$27B of AB InBev market value, and permanently ceded the ~22-year US #1 volume crown — Bud Light fell to #2/#3 and remained ~40% below pre-boycott levels into 2025, never recovering. It proved these brands command a premium but are not invulnerable, and that US mainstream-lager brand equity in particular is perishable. (The consolation: AB InBev’s own Michelob Ultra became the #1 US beer by retail dollar sales by September 2025, and Busch Light is a share gainer — the US portfolio migrated up-market even as Bud Light shrank. Be precise, though: on supplier share AB InBev has ceded high-end ground to Constellation over the cycle; the win is at the brand/mix level, not obviously at the total-US-share level.)

Financial proof of moat. Gross margin ~56%, EBITDA margin ~36% (best-in-class among global brewers), pricing power demonstrated by +4.4% revenue/hl in a down-volume year, and share stability/gains in ~80% of markets in Q4 2025. The moat is proven in margins and share — but note it does not show up in ROIC (~7%), because the price paid for the acquired brands (goodwill) is so high that even excellent operating economics earn only a market-average return on the capital as booked. On unencumbered/organic invested capital the returns are far higher; on an acquirer’s-cost basis they are mediocre.

Verdict: a durable, genuinely wide moat — but one that guarantees stability and pricing power, not compounding growth. This is a fortress around a slowly-growing (in aggregate) territory, strongest exactly where AB InBev owns the route-to-market and dominant local share (Mexico ~56%, Brazil, Colombia, South Africa) plus the BEES data/network layer, and weakest where it is sub-scale (China) or where the crown-jewel brands enrich a rival (US Modelo/Corona → Constellation). Best-in-class where it leads; vulnerable where it doesn’t.

5. Growth History and Forward Opportunities

History. AB InBev’s growth story is a tale of two metrics. Organic revenue has grown low-single-digits (FY2025 +2%; a multi-year ~5–8% organic pace pre-2023 that has decelerated), driven overwhelmingly by revenue/hl (price + mix, +4.4% in FY2025) rather than volume — total volume was 561.1m hL, −2.3% in FY2025 (own-brands/STRs −3.2%), the multi-year pattern of shrinking volumes offset by price. Reported USD revenue has been roughly flat at ~$57–60B for four years because EM-FX translation has eaten the organic gains. Underlying EPS, by contrast, compounded ~6.7%/yr since 2021 — the gap between EBITDA growth (~4–5%) and EPS growth (~6.7%) is the deleveraging + buyback engine: falling interest expense and a shrinking share count.

Forward opportunities (ranked by credibility):

1. Premiumization (high credibility). AB InBev’s “mega brands” (Corona, Budweiser, Stella, Michelob Ultra, etc.) are 57% of revenue and growing ~10%/yr; premium beer is forecast to grow at >2x the category rate. This is the most reliable growth lever — it works in every geography and is margin-accretive.
2. BEES Marketplace (medium-high). A genuine new revenue stream ($3.5B GMV, +61%) addressing the ~60% of retailer wallet that isn’t beer, with attractive incremental margins as the 3P/touchless mix scales. Early but real optionality.
3. Beyond Beer & non-alcohol (medium). Beyond Beer (+23% revenue) and non-alc beer (+34%) are growing fast off small bases (Beyond Beer ~3% of revenue). Cutwater (US RTD cocktails, triple-digit growth), NÜTRL, Corona Cero, Michelob Ultra Zero. Margin-accretive and taps non-beer occasions, but not yet needle-moving at the group level.
4. Emerging-market per-capita growth (medium, macro-dependent). The structural bull case — low per-capita consumption in Africa/LatAm with demographic tailwinds — but gated by EM currency and macro volatility.
5. US turnaround (medium). Michelob Ultra + Busch Light were the top-2 US volume-share gainers in 2025; the US grew industry-share in beer and spirits. Real, but on a structurally declining US volume base.
6. China recovery (low-medium, show-me). Currently a drag (revenue −low-teens); management is reorganizing toward off-trade/inland. Optionality if it inflects, but no credit deserved yet.

Quality of the growth. Medium-to-good. It is high-margin, brand-led, and cash-generative — but it is predominantly price/mix, not volume, which is inherently more fragile (there is a ceiling to how far you can out-price a shrinking-volume category before you accelerate the volume decline). The highest-quality growth (premiumization, BEES Marketplace, Beyond Beer) is real but small relative to the ~$59B base. The single most important swing factor is whether volume returns — 2025 exited with improving momentum (December inflection) and management sounds cautiously optimistic on 2026 (World Cup, US momentum, Brazil recovery), but volume has disappointed for several years running.

Verdict: low-single-digit, price/mix-driven, medium-quality growth with credible-but-small optionality on top. Not a growth stock; a compounder whose per-share growth has been flattered by deleveraging that is now maturing.

6. Financial Quality

Revenue & margins. FY2025 revenue $59.32B (+2% organic; USD ~flat). Gross margin 55.9% (up from ~53.9% in 2023 as input-cost inflation eased and mix improved), EBITDA $21.30B / 35.9% margin (+101bps YoY — the fourth straight year of margin recovery toward the ~38–39% pre-COVID peak), operating income $15.65B / 26.4%. Margins are best-in-class among global brewers and structurally supported by premiumization + ZBB cost discipline. Management guides continued margin expansion “over time.”

Earnings quality — the GAAP-vs-underlying wedge. This is the single most important quality-of-earnings issue. AB InBev reports an IFRS basic EPS of $3.45 (diluted ~$3.39) but an “underlying EPS” of $3.73 for FY2025. The reconciling items are largely non-cash and non-operating: (i) the notorious mark-to-market on the derivative that hedges the share-based-payment programs and the shares issued for the Grupo Modelo/SABMiller deals — a −$213M finance hit in 2025, but a much larger −$1,211M in 2024 (the drag shrinks when the share price rises, and vice-versa — i.e. AB InBev is effectively short its own stock through this line); (ii) Argentina hyperinflation (IAS 29) accounting, which together with FX cut reported revenue by ~$1.3B in 2025; and (iii) a $1,143M non-cash impairment in share-of-associates plus assorted disposal gains. These are legitimate exclusions in principle (non-operating), but several recur every year, so “underlying” is the right lens provided one remembers the hedge MtM is real, price-sensitive, cash-adjacent economics tied to the balance-sheet legacy. The gap is modest in 2025 (~$0.28–0.34) and has narrowed as the balance sheet de-risks and the share price recovered — a genuinely positive signal. Ratings confirm the improvement: S&P A-/A-2 (positive outlook), Moody’s A3/P-2.

Cash flow — the real strength. This is where AB InBev shines. FY2025 CFO $14.88B; capex only $3.66B (6.2% of sales, and below D&A of $5.65B); free cash flow ~$11.2B (~$5.66/share). Capex has fallen from ~$5.6B in 2021 as management leans on technology/AI for efficiency — sustainable at the ~$3.5–4B guided level given the mature asset base, though a multi-year run below depreciation bears watching (it can flatter near-term FCF at the expense of eventual reinvestment). Cash conversion is excellent (CFO/net income >2x), and working capital is a structural benefit: the cash-conversion cycle is deeply negative (−137 days) — suppliers and the negative-working-capital model of a fast-moving consumer product effectively finance the business. FCF comfortably covers dividends (~$4.5B), the buyback, and debt reduction.

Returns on capital — the core weakness. ROE 13.6%, ROIC ~6.9%, ROA 3.2%. ROIC has been remarkably stable at 5.8–6.9% every year 2019–2025 (COVID 2020 excepted) — i.e. persistently at or below the ~7–8% WACC. This is the acquisition-goodwill problem: the operating business earns high returns on tangible capital, but on the ~$160B of goodwill+intangibles booked at acquisition cost, the blended return is market-average. The honest read: AB InBev has been, at the consolidated level, a capital-preserving rather than capital-compounding enterprise since the SABMiller deal. Value creation has come from FCF generation and balance-sheet repair (turning debt into equity value), not from earning excess returns on incremental capital.

Balance sheet. The defining feature. Total debt $73.0B, cash $11.5B, net debt $59.1B, plus $10.4B minority interest (Ambev/others). Net debt/EBITDA 2.77x (ROIC basis) / 2.87x (company basis) — down from 4.65x in 2020, the clearest evidence of the deleveraging thesis working. Debt is well-termed: weighted-average maturity ~13 years, no 2026 maturities, no financial covenants, investment-grade (A-area) ratings, mostly fixed-rate, currency-matched to cash flows. Interest coverage (EBITDA/interest) ~5.5x and rising. Tangible book equity is deeply negative (−$31.3/share) — meaningless as a valuation anchor for a brand business, but a reminder that book value here is ~$160B of intangibles.

Verdict: economics are stable and cash-rich, not improving-with-scale in ROIC terms. This is a superb cash-flow franchise sitting on a legacy balance sheet that is finally normalizing. The FCF and margin trajectory are genuinely good; the ROIC-≈-WACC reality caps how good the investment can be. Economics do not meaningfully improve with scale here — they are already at scale; what improves is the capital structure.

7. Capital Allocation

The defining decision: SABMiller (2016). AB InBev bought SABMiller for >$100B — the largest consumer-staples deal in history — at what proved to be a cyclical/valuation top, funding it with ~$40B+ of new debt and equity (including the deferred/restricted “PRS” shares issued to Altria and BEVCO). It created ~$118B of goodwill and took net leverage to ~4.8–5.6x. Judged on returns, it was value-destructive at the price paid: the acquired earnings never justified the ~$100B+ of capital, and the subsequent decade of deleveraging, two dividend cuts (2018, 2020), and a de-rated stock is the bill. This is the central capital-allocation fact about AB InBev, and it colors everything: management’s credibility on big capital deployment is poor.

The redemption arc: deleveraging (2016–present). To its credit, management then executed a disciplined, multi-year deleveraging with genuine skill: cutting the dividend when necessary (unpopular but correct), prioritizing debt paydown, actively managing the maturity profile (terming out to ~13 years, eliminating covenants, no near-term walls), and only resuming shareholder returns once leverage was safely below ~3x. Net debt fell from ~$81B (2020) to ~$59B (2025); gross debt from ~$99B to $73B. This is a well-run balance-sheet repair, and it is the source of most of the equity’s recent return.

Current capital-return framework (inflecting positively). With leverage normalized, capital allocation is shifting from “all debt paydown” to a balanced return: dividend cut in 2018 (halved) and again in 2020 (to €0.50) to fund deleveraging, then progressively rebuilt — FY2025 dividend €1.15/share, +15% YoY (€0.15 interim + €1.00 proposed final), with a progressive-dividend ambition. On buybacks, AB InBev completed a $2B program (finished June 2025), and in October 2025 announced a new $6B, 24-month program (~$635M executed by early Feb 2026) — cumulatively ~$3.2B of buybacks completed to date. It also repurchased ~$6B of bonds while issuing ~€3.2B in 2025, terming out the maturity profile. Payout ratio ~45% on GAAP, comfortably FCF-covered. A rational, shareholder-friendly framework — belated, but appropriate now. One structural overhang to note: Altria is a persistent, price-insensitive seller of its legacy stake (down to ~8.1% from ~10% via a 35m-share secondary at $61.50 in early 2026, alongside a ~$200M direct buyback by AB InBev) — a recurring supply headwind on the stock, not a governance signal.

Reinvestment & bolt-ons. Capex is disciplined (~6% of sales, below D&A). M&A since the SABMiller integration has been small and sensible — bolt-ons in Beyond Beer (BeatBox), energy (Phorm Energy), and technology, plus the large divestiture of Carlton & United (Australia) to Asahi for ~$11B in 2020 to fund deleveraging. S&M at ~$7.4B/yr (~12–13% of revenue) is the real “growth capex” of a brand business and is well-spent (record brand power, US share gains). R&D-equivalent is product/liquid innovation (11% of revenue from innovations).

Governance & incentives. A controlled company: the Stichting Anheuser-Busch InBev (the Belgian founding-family + 3G Capital vehicle — de Spoelberch, de Mévius, Van Damme families with EPS/BRC) held 33.99% of shares at end-2025, and the family concert controls ~39.5% of voting rights — enough to elect a majority of the board and block dilutive actions, insulating the company from activism or a hostile bid. Legacy Restricted Shares from the SABMiller deal (held by Altria and BEVCO/the Santo Domingo family; ~222M still outstanding, convertible 1-for-1 since Oct 2021) round out the register. Incentive design carries two flags: (i) options and capital decisions are explicitly tied to EBITDA targets and deleveraging progress — not ROIC (fully consistent with the 3G/ZBB heritage of margin-and-cash discipline over invested-capital returns, and a tell as to why ROIC has languished at WACC); and (ii) the CEO’s FY2025 package carried a headline value of ~€90M (base €1.36M + bonus €3.48M + an equity grant valued at ~€85.8M) — mostly long-dated contingent equity, but eye-watering optics against roughly-flat reported revenue. Insider signal from the EDGAR record is negligible (as an FPI, executives don’t file routine Form 4s; the only recent item is a trivial 2,000-share director sale via Form 144); the one meaningful “insider” flow is Altria’s ongoing exit.

Verdict: a study in contrasts — one catastrophic, value-destructive mega-deal (SABMiller at the top), redeemed by a decade of genuinely skilled balance-sheet repair and a now-rational, inflecting capital-return framework. The forward setup is good (disciplined capex, rising dividends, buybacks, low-A credit); the history, the empire-building DNA, the EBITDA/deleveraging-not-ROIC incentive design, and the €90M pay optics all demand permanent skepticism about the next big deal. Grade: below the quality of the underlying business — improving, but the SABMiller scar is real.

8. Changes and Headwinds — Last Two Years

Positive changes (thesis-strengthening):

• Deleveraging crossed the psychological ~3x threshold (2.87x company basis), unlocking the dividend increase and buyback — the proximate cause of the 2025–2026 re-rating.
• US turnaround took hold. Michelob Ultra and Busch Light were the top-2 US volume-share gainers in 2025; the US gained share in both beer and spirits — a genuine reversal of a multi-year structural-disadvantage narrative and the post-Bud-Light trough.
• Volume momentum inflected in Q4 2025 / December, carrying into early 2026, after several years of “below potential” volumes.
• BEES + Beyond Beer + non-alc scaling (Marketplace GMV +61%, Beyond Beer +23%, non-alc +34%) — the growth-optionality portfolio is compounding fast.
• Margin expansion resumed (+101bps in 2025, four straight years of recovery).
• World Cup 2026 (North America) + Winter Olympics + Budweiser 150th anniversary — a heavy 2026 activation calendar management is leaning into.

Headwinds (thesis-pressuring):

• China is a live drag — revenue down low-teens in 2025 on channel/geographic mix; a multi-quarter reorganization with no clear inflection yet.
• Persistent EM-FX translation has kept USD revenue flat for years and remains the biggest swing factor in reported results (BUD’s USD factor beta is −0.47 — a strong dollar directly hurts).
• The 2023 Bud Light boycott’s permanent legacy — Modelo displaced Bud Light as US #1 and has not given it back; the US flagship is structurally smaller.
• Secular developed-market volume decline — moderation, Gen Z abstinence, GLP-1 drugs, cannabis substitution — a slow but real headwind to the ~30% developed-market profit base.
• Weak/uneven consumer across several markets in 2025 (Brazil H1 weather + disposable-income stress; European industry softness).
• Input costs / tariffs — aluminum, barley, energy, and potential US tariff exposure on aluminum/imported inputs are recurring margin risks (hedged ~1 year out, so 2026 H1 carries the 2025-FX cost drag).

Verdict: on balance thesis-strengthening over the last two years — the deleveraging milestone, US turnaround, margin recovery, and volume inflection are meaningful positives that the market has (correctly) rewarded. But the strengthening is precisely why the easy upside is gone; the remaining headwinds (China, secular volume, FX) are the ones the current price must now navigate for further gains.

9. Risk Analysis

Overall: No single existential risk (the balance sheet is now managed, the business is diversified and cash-generative), but a cluster of slow-moving structural headwinds (developed-market volume, EM-FX, China) that cap the growth ceiling and make the stock’s forward return dependent on execution and macro rather than on a cheap starting multiple. The tail risk that matters is a repeat of undisciplined mega-M&A now that leverage capacity is returning.

10. Valuation Discussion (embedded expectations)

Where it trades (2026-07-10, $79.61). With ~1.99B shares, equity value ≈ $155–158B; adding ~$59B net debt and ~$10.4B minority interest gives an enterprise value of ~$224B. Against FY2025 figures:

The leverage lens (critical). BUD’s optically-high P/E (~21x underlying) against a moderate ~9.5–10x EV/EBITDA is not a contradiction — it is financial leverage. ~$3.9B of annual interest expense sits between EBITDA and net income, so the equity is a levered claim on the enterprise: a modest EV/EBITDA multiple translates into a higher P/E. The corollary is the bull mechanic — as AB InBev delevers, interest expense falls and EPS grows faster than EBITDA (the ~6.7% EPS CAGR vs. ~4–5% EBITDA growth). This is real and ongoing, but decaying: the closer leverage gets to the ~2x target, the smaller the incremental interest-savings kicker.

Peer context. Constellation (STZ, the US Modelo/Corona owner) trades ~11x EV/EBITDA / ~12.4x comparable P/E at ~3.2x leverage with a ~39% beer margin (bottom-decile own-history — genuinely cheap); Heineken ~9–10x EV/EBITDA; Molson Coors ~7–8x (structurally-challenged, cheapest); premium non-alc staples (KO, PEP) at richer multiples. AB InBev at ~9.5–10x EV/EBITDA sits mid-pack among brewers — cheaper than STZ’s quality but STZ is cheaper on its own history; more expensive than Molson Coors but far higher-quality. On P/E, BUD looks dear versus STZ purely because of leverage. Net: BUD is fairly valued relative to peers, not conspicuously cheap or dear.

Embedded-expectations analysis — what must be true at ~$80? At ~9.5–10x EV/EBITDA and ~7% FCF yield, the market is underwriting roughly:

• Mid-single-digit EBITDA growth continuing (in line with the +4–8% organic guide, hit toward the lower-middle in USD after FX);
• Leverage normalizing toward ~2–2.5x, sustaining the EPS>EBITDA growth wedge for another ~2–3 years;
• Margins continuing to expand modestly toward the high-30s;
• No return to distress and no repeat value-destructive mega-deal.

That is a reasonable and largely-already-visible base case — which is the point: the price now reflects the successful turnaround. For the stock to compound meaningfully from here, one of two things must happen that the price is not paying for: (a) durable volume growth returns (Brazil + US + China stabilization) re-rating BUD toward a true 11–12x staples multiple, or (b) the EM-FX headwind reverses (weak dollar), flattering reported results. Conversely, the price is not discounting the bear scenario — a confirmed structural volume decline in the developed world with EM growth stalling — which would justify a de-rate back toward the low-$60s / ~8x EBITDA (roughly the mid-2025 level).

Scenario sketch (illustrative, not a target):

• Bear (~$58–65): volume decline confirmed secular, China stays broken, strong USD persists → ~8x EBITDA, EPS growth fades to low-single-digits as deleveraging matures.
• Base (~$75–88): mid-single-digit EBITDA growth, leverage to ~2x, buyback + progressive dividend, ~9.5–10.5x EBITDA → the equity compounds roughly with FCF yield + modest growth (~high-single-digit total return).
• Bull (~$95–110): volume growth returns durably, EM-FX turns tailwind, BEES Marketplace scales into a visible profit line → re-rate to ~11–12x EBITDA on faster growth.

No price target; no recommendation (see the relevant section/the relevant section). The valuation read: fair, mid-range, balanced risk/reward — the distressed-multiple asymmetry that existed at $46 is gone.

11. Variant Perception

Consensus view. The sell-side skews constructive-to-positive: roughly a Buy/Overweight majority with a scattering of Holds, and an average price target around $90–94 (range ~$74 to ~$105) as of mid-2026 — JPMorgan raised to ~$94, Goldman/Bernstein/Evercore/Wells Fargo at Buy, Morgan Stanley OW ~$84.5, Deutsche Bank and TD Cowen at Hold (~$89), and Jefferies the notable bear at ~$74. The wide dispersion ($74 vs $105) is the whole debate: margin-and-deleveraging compounding (bulls) vs. structural volume decline (bears). The consensus narrative: “quality global brewer, deleveraging done, US turned, EM growth optionality, BEES optionality, buyback support — own it as a defensive compounder.” The market has re-embraced BUD as a low-beta, dividend-growing, min-vol staple (its factor peers are literally min-vol and dividend ETFs plus Pernod Ricard and Takeda).

Strongest bull case. AB InBev is a wide-moat global champion at the start of a virtuous phase: leverage finally normalized frees capital for accelerating buybacks and dividends; the US has genuinely turned; premiumization + BEES + Beyond Beer are compounding; ~70% EM exposure is the right place to be for the next decade of category growth; and if the dollar weakens, years of suppressed reported results flip to tailwind. On this view the ~7% FCF yield + mid-single-digit growth + rising capital return compounds to low-double-digit total returns, with a re-rate option if volumes inflect.

Strongest bear case. You are buying a no-real-growth, ROIC-≈-WACC volume business whose per-share numbers have been flattered by a self-liquidating deleveraging tailwind that is now ~80% spent, at a mid-range (58th-percentile) valuation after a 70% run, with the developed-world volume base in slow secular decline (moderation, GLP-1, Gen Z, cannabis), China broken, EM-FX a persistent drag, and a management team whose one big capital decision this century (SABMiller) destroyed enormous value — and who now, with leverage capacity returning, has the means to do it again. On this view the easy money is made and forward returns are pedestrian (FCF yield minus multiple risk).

The 3–5 assumptions that matter most:

1. Does developed-market beer volume stabilize or structurally decline? (The single biggest long-run swing — GLP-1/moderation evidence is the key unknown.)
2. Does EM per-capita/premiumization growth durably offset developed-market decline in volume terms, not just price?
3. Does the dollar strengthen or weaken over the holding period? (Directly moves ~70% of reported EBITDA.)
4. Does management stay disciplined on capital as leverage capacity returns, or repeat SABMiller?
5. Does China inflect? (Optionality, not base case.)

Falsification: The bull breaks if 2026–2027 volumes disappoint again and the +4–8% organic guide is missed to the downside (proving the December-2025 inflection was a head-fake). The bear breaks if AB InBev prints two to three consecutive quarters of positive organic volume growth across its major markets with stable-to-weak dollar — which would validate a re-rate to a full staples multiple.

Our variant read: We are less enthusiastic than the constructive consensus — not because the business is worse than believed, but because the price now embeds the good news. The factor tape confirms this: the stock has already flipped from falling-knife to crowded-recovery-momentum (rs_6m +28%, above all moving averages), and the valuation is mid-range, not cheap. The variant perception is that the market is paying a re-rated price for a business whose structural growth ceiling and ROIC≈WACC reality haven’t changed — the turnaround was real, and it is now in the price.

12. Fact vs. Interpretation Table

13. Open Questions

1. What is the real organic volume trajectory in 2026? Was the December-2025 inflection durable, or weather/comps noise? (The whole bull case rests on volume returning.)
2. What does the GLP-1 / moderation evidence actually show for beer specifically (vs. spirits/wine), and over what timeframe? Is developed-market decline −1% or accelerating?
3. China: is there a credible path to inflection, or is AB InBev structurally sub-scale in the mass segment there?
4. How much further can capex run below D&A before it becomes under-investment that shows up in volume/share?
5. What is management’s next big capital move as leverage hits ~2x — accelerated buyback (good) or a return to M&A ambition (the SABMiller tail risk)?
6. Precise ownership/control mechanics — the founder-family control vehicle, Altria’s remaining stake and any sell-downs, and how incentives are structured post-deleveraging. [Pending filings research.]
7. How large can BEES Marketplace + Beyond Beer become as a share of profit — genuine new profit pool, or perpetual “small but growing fast”?

14. What Must Be True

Bull case — what must be true:

• Developed-market volume stabilizes (not accelerating-declines) while EM volume + global premiumization drive +2–3% organic volume, lifting organic revenue toward the mid-single-digits sustainably.
• Leverage reaches ~2x with the freed capital going to accelerating buybacks + progressive dividends (not a mega-deal), sustaining EPS growth ahead of EBITDA.
• Margins continue toward the high-30s; BEES Marketplace + Beyond Beer scale into a visible incremental profit line.
• The dollar is stable-to-weak, letting organic gains flow to reported USD results.
• Falsification test: Two-plus consecutive quarters of the +4–8% organic EBITDA guide being missed to the downside on renewed volume weakness in 2026–2027 — would prove the inflection was a head-fake and the business is a price/mix-only, ceiling-bound compounder.

Bear case — what must be true:

• Beer volume in the developed world is in confirmed structural decline (GLP-1 + moderation + Gen Z + cannabis), and EM growth decelerates / is eaten by FX — so organic volume stays negative and price/mix hits its ceiling.
• The deleveraging EPS tailwind fully matures (~2x reached), removing the wedge that made EPS grow faster than a flat-ish EBITDA base.
• Management, with leverage capacity restored, pursues another large, value-destructive acquisition.
• Falsification test: Three consecutive quarters of positive organic volume growth across the major markets (Brazil, US, EM) with a stable-to-weak dollar — would validate a durable-growth re-rate and break the “no-growth, already-re-rated” bear thesis.

15. Source Appendix

See the Source Appendix (Appendix B) below for the full itemized source list with URLs and access dates. Primary sources: AB InBev FY2025 Form 20-F (filed 2026-03-03, SEC EDGAR CIK 0001668717); FY2025 full-year earnings call transcript (12 Feb 2026); company financial data reconciled to the 20-F (statements, ratios, valuation multiples, per-share, enterprise value); public news feeds and own-history valuation percentiles; 5-year daily price history; public factor-model data (loadings, risk-adjusted returns, factor peers); and public beverage-sector comparables (Constellation Brands, Coca-Cola Europacific Partners, Coca-Cola, PepsiCo) for cross-read.

APPENDIX A — Standard Diligence Questionnaire

APPENDIX B — Source Appendix

Anheuser-Busch InBev SA/NV (NYSE: BUD) — report date 2026-07-11. All web sources accessed 2026-07-11. Primary sources listed first; third-party aggregated data reconciled to filings.

Primary — company filings & disclosures

• Form 20-F, FY2025 (annual report), filed 2026-03-03. SEC EDGAR, CIK 0001668717. https://www.sec.gov/Archives/edgar/data/1668717/000119312526088105/d65314d20f.htm.
• FY2025 full-year results & earnings call transcript, 11–12 Feb 2026 (CEO Michel Doukeris, CFO Fernando Tennenbaum). Press release BusinessWire 2026-02-11.
• Form 6-K filings (interim results, dividends, buyback announcements), SEC EDGAR 2025–2026, CIK 0001668717.
• Schedule 13D/A filed 2026-05-15 (Altria stake); Form 144 filed 2026-02-13. SEC EDGAR.
• AB InBev Investor Relations / FY2025 Q4 results deck (via Investing.com). https://www.ab-inbev.com

Data sources

• Company financial statements, ratios, and valuation multiples (FY2016–FY2025) reconciled to the Form 20-F; earnings-call transcript (Q4 2025).
• Public news feeds; own-history valuation percentile context; 5-year daily price history (2009–2026, adjusted/unadjusted OHLCV, moving averages, beta/alpha).
• Public factor-model data — factor loadings, risk-adjusted return history, beta/alpha/relative-strength, factor-similar peers.
• SEC EDGAR full-text & XBRL (CIK, filings index).

Industry, competitive & thematic sources

• BarthHaas Report 2024/25 (top-40 global brewers by volume), via Craft Brewing Business / VinePair. https://www.craftbrewingbusiness.com/business-marketing/new-barthhaas-report-reveals-2024s-top-40-biggest-global-brewers/
• Statista — AB InBev market share & company topic page. https://www.statista.com/topics/1904/anheuser-busch-inbev-ab-inbev/
• Constellation Brands US Modelo/Corona rights (2013 AB InBev–Grupo Modelo remedy). https://www.cspdailynews.com/beverages/anheuser-busch-inbev-completes-combination-grupo-modelo
• Bud Light boycott (Apr 2023) — timeline & impact. https://en.wikipedia.org/wiki/Bud_Light_boycott ; https://beerconnoisseur.com/articles/bud-light-boycott-continues-impact-brand-drops-third-place-us-beer-sales
• Modelo Especial / Michelob Ultra US #1 dynamics. https://beerconnoisseur.com/articles/modelo-especial-surpasses-bud-light-americas-top-beer-sales-data-reveals ; CNBC (Sept 2025).
• US beer volume decline — Beer Marketers Insights; Brewers Association 2025 Year in Beer. https://www.brewersassociation.org/association-news/the-2025-year-in-beer/
• Moderation / Gen Z drinking (Gallup 62%→54%). https://leger360.com/en/market-intelligence-beyond-the-buzz-2025-sober-curious/
• GLP-1 & alcohol consumption evidence (semaglutide −41%; JAMA 45.3%). https://www.beveragedaily.com/Article/2025/06/18/what-do-weight-loss-drugs-mean-for-alcohol-brands/ ; https://www.ey.com/en_us/insights/consumer-products/glp-1-shifts-alcohol-market-dynamics
• Cannabis/THC-beverage substitution. https://www.brewersassociation.org/insights/how-much-does-thc-take-from-beer/
• US 25% Section 232 tariff on imported canned beer + aluminum cans (Apr 4 2025). https://www.cnbc.com/2025/04/02/trump-puts-tariffs-on-canned-beer-imports.html ; https://www.federalregister.gov/documents/2025/04/04/2025-05884/
• BEES B2B digital platform metrics. https://www.digitalcommerce360.com/2025/05/08/ab-inbev-b2b-digital-sales-revenue-q1-fy25/
• Grupo Modelo Mexico share (~56–57%). https://en.wikipedia.org/wiki/Grupo_Modelo
• Guinness/Diageo growth. https://www.beveragedaily.com/Article/2025/01/27/guinness-is-not-for-sale-says-diageo/
• 2026 sell-side positioning (MarketBeat / StockAnalysis consensus & PTs). https://www.marketbeat.com/stocks/NYSE/BUD/forecast/

Cross-referenced public comparables

• Constellation Brands (STZ — US Modelo/Corona owner; beer margin & valuation comps); Coca-Cola Europacific Partners, Coca-Cola, PepsiCo, Keurig Dr Pepper, Brown-Forman (beverage-sector framing).